IDH1 and cholangiocarcinoma: A retrospective analysis of the ClarIDHy trial, which examined the efficacy of the IDH1 inhibitor ivosidenib in mutant IDH1 cholangiocarcinoma, showed that the clearance of IDH1 mutation, as assessed in plasma ctDNA in patients monitored over time, was associated with disease control [149].